Autochthonous Plasmodium vivax Infections, Florida, USA, 2023
Azhar Muneer
1, Swamy R. Adapa
1, Suzane Silbert, Kelly Scanlan, Harold Vore, Andrew Cannons, Andrea M. Morrison, Danielle Stanek, Carina Blackmore, John H. Adams, Kami Kim
2, Rays H.Y. Jiang
2, and Liwang Cui
2
Author affiliations: University of South Florida Morsani College of Medicine, Tampa, Florida, USA (A. Muneer, K. Kim, L. Cui); University of South Florida School of Public Health, Tampa (S.R. Adapa, J.H. Adams, K. Kim, R.H.Y. Jiang); Tampa General Hospital, Tampa (S. Silbert, K. Kim); Sarasota Memorial Hospital, Sarasota, Florida, USA (K. Scanlan, H. Vore); Florida Department of Health Bureau of Public Health Laboratories, Tampa (A. Cannons); Florida Department of Health, Tallahassee, Florida, USA (A.M. Morrison, D. Stanek, C. Blackmore)
Main Article
Figure 1
Figure 1. Identification of Plasmodium vivax infections in blood samples from malaria patients, Florida, USA, May–July 2023. Image shows 117-bp PCR products amplified from blood samples from 4 patients by using P. vivax–specific primers targeting the 18S rRNA gene. M, DNA ladder.
Main Article
Page created: April 25, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.